Holen Sie sich die Stockscreener-App
93.34
1.06%
-1.00
Vorhandelsmarkt:
93.40
0.06
+0.06%
Schlusskurs vom Vortag:
$94.34
Offen:
$94.29
24-Stunden-Volumen:
857.53K
Relative Volume:
0.92
Marktkapitalisierung:
$5.10B
Einnahmen:
$1.34M
Nettoeinkommen (Verlust:
$-173.66M
KGV:
-22.55
EPS:
-4.1385
Netto-Cashflow:
$-130.49M
1W Leistung:
-2.45%
1M Leistung:
+15.94%
6M Leistung:
+157.85%
1J Leistung:
+395.17%
1-Tages-Spanne:
$90.52
$97.48
1-Wochen-Bereich:
$87.40
$98.70
52-Wochen-Spanne:
$17.88
$98.70
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
929-999-4055
Adresse
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
93.34 | 5.33B | 1.34M | -173.66M | -130.49M | -4.1385 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-10-14 | Eingeleitet | Truist | Buy |
| 2025-07-02 | Eingeleitet | William Blair | Outperform |
| 2024-12-20 | Eingeleitet | TD Cowen | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-15 | Eingeleitet | Stifel | Buy |
| 2023-12-26 | Eingeleitet | Jefferies | Buy |
| 2023-11-22 | Eingeleitet | Wedbush | Outperform |
| 2023-10-30 | Eingeleitet | Guggenheim | Buy |
| 2023-09-28 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-20 | Fortgesetzt | Goldman | Neutral |
| 2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Bestätigt | B. Riley Securities | Buy |
| 2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-07 | Eingeleitet | Mizuho | Buy |
| 2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
| 2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Price to book forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch - Stocktwits
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell 2000 Value Benchmark - marketscreener.com
Dianthus Therapeutics stock hits 52-week high at 96.85 USD - Investing.com
Dianthus launches phase 3 trial for myasthenia gravis treatment By Investing.com - Investing.com UK
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis - The Manila Times
Dianthus launches Phase 3 study of claseprubart in rare muscle disease - Stock Titan
Dianthus Therapeutics, Inc.(NasdaqCM: DNTH) dropped from Russell 3000E Index - marketscreener.com
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell 2500 Value Benchmark - marketscreener.com
Price to earnings forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
Price to sales forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
Enterprise value to EBIT forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
Price to book forward of Dianthus Therapeutics, Inc. – DUS:87E - TradingView
Enterprise value to EBITDA forward of Dianthus Therapeutics, Inc. – DUS:87E - TradingView
Dianthus drops as Sanofi halts late-stage trial for CIDP therapy on efficacy concerns - MSN
DNTH Forecast — Price Target — Prediction for 2027 - TradingView
Dianthus Therapeutics, Inc. Actuals & Estimates (FWB:87E) - TradingView
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
A3ERZ4 Forecast — Price Target — Prediction for 2027 - TradingView
Dianthus Therapeutics Inc (DNTH) Valuation: PE, PB & Fair Value Analysis - TradingKey
Why is Dianthus Therapeutics stock trading higher on Friday? - MSN
DNTH Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Dianthus (DNTH) SVP uses 10b5-1 plan to sell 30,000 shares - Stock Titan
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results - Stocktwits
Dianthus Therapeutics Inc (DNTH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dianthus Therapeutics Inc (DNTH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dianthus Therapeutics Inc (DNTH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing - Stock Titan
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It? - The Globe and Mail
Wells Fargo Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $135 - Moomoo
Dianthus Therapeutics Inc (DNTH) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dianthus Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | 87E | US2528281080 - marketscreener.com
Dianthus Therapeutics Inc (DNTH) Institutional Confidence - TradingKey
Dianthus Therapeutics Inc (DNTH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dianthus Therapeutics Inc (DNTH) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Medpace Holdings (MEDP) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Dianthus Therapeutics (DNTH) - The Globe and Mail
Dianthus Therapeutics (DNTH) Stock After CAPTIVATE Results Looks Fairly Valued - Sahm
DNTH stock clocks best day in over 3 months on strong nerve disorder study results - MSN
DNTH News | DIANTHUS THERAPEUTICS INC (NASDAQ:DNTH) - ChartMill
Dianthus CIDP Data Lift Prospects While Funding And Dilution Risks Linger - Yahoo Finance
Truist Financial Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating - Moomoo
Avidity Partners Management LP Sells 1,100,000 Shares of Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Why Is Dianthus Therapeutics Stock Trading Higher On Friday?Dianthus Therapeutics (NASDAQ:DNTH) - Benzinga
Dianthus Therapeutics posts interim CAPTIVATE responder data; 75% response in first 40 CIDP patients - TradingView
Dianthus Therapeutics (DNTH) details interim Phase 3 CIDP results, Phase 2 gMG data and $1.2B runway - Stock Titan
Dianthus Therapeutics: Sanofi's CIPD Study Fail Poses Uncomfortable Questions - Seeking Alpha
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says - Benzinga
Analysts’ Top Healthcare Picks: Dianthus Therapeutics (DNTH), Cullinan Management (CGEM) - The Globe and Mail
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Dianthus Therapeutics Inc-Aktie (DNTH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Veness Adam M | SVP, General Counsel and Sec. |
Jun 17 '26 |
Sale |
80.80 |
30,000 |
2,423,958 |
0 |
0.05%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):